Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges
Takeya Adachi(Keio University), Duangrurdee Wattanasirichaigoon(Mahidol University), Marshall Summar(Children's National), Camila I. Quirland Lazo(Universitat Autònoma de Barcelona), Katya A. Nogales Crespo, Ayman W. El‐Hattab(King Saud bin Abdulaziz University for Health Sciences), Ritu Jain(Nanyang Technological University), Maurizio Scarpa(University of Udine)
International Journal of Environmental Research and Public Health
March 8, 2023
Cited by 157
Related Papers
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Mitochondrial DNA Depletion Syndromes: Review and Updates of Genetic Basis, Manifestations, and Therapeutic Options
|Neurotherapeutics|2013|337
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
|Journal of Cerebral Blood Flow & Metabolism|2012|307
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
|Journal of Inherited Metabolic Disease|2011|302